Premium
Outcomes of Macroplastique injections for stress urinary incontinence after suburethral sling removal
Author(s) -
Rodríguez Dayron,
Carroll Timothy,
Alhalabi Feras,
Carmel Maude,
Zimmern Philippe E.
Publication year - 2020
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.24321
Subject(s) - medicine , urinary incontinence , urology , sling (weapon) , surgery
To evaluate outcomes following urethral Macroplastique (MPQ) injection in women with stress urinary incontinence (SUI) following suburethral sling removal (SSR) for synthetic sling complications. Methods Following Institutional Review Board approval, charts of non‐neurogenic women with SUI after SSR who underwent MPQ injection(s) and had at least 6 months minimum follow‐up were reviewed from a prospectively maintained database. Demographic data, questionnaire (Urogenital Distress Inventory‐6 [UDI‐6] and Quality of Life) scores, and pad usage were recorded. Patients were followed with repeat questionnaires and three‐dimensional ultrasound evaluating MPQ volume. Success following MPQ was defined as a composite score of a UDI‐6 question 3 score of 0 to 1 at last visit and no additional anti‐incontinence therapy. Results From 2011 to 2018, 70 women with mean age 62.7 years met study criteria. At a mean follow‐up of 46.4 ± 1.5 months, the success rate after the first MPQ injection was 46%. Following a repeat MPQ injection when indicated, the overall success rate for the entire cohort was 69%. Despite the objective failure, the majority of patients reported subjective improvement (83%) and reduced pad usage (78%). On multivariate analysis: age, body mass index, previous hysterectomy, hormone replacement therapy, type of sling removed and baseline urodynamics (UDS) parameters were not predictors of MPQ failure. Higher parity was a predictor of MPQ failure (hazard ratio = 1.980; P = .032). Conclusion MPQ injection is a durable and effective management option for SUI following SSR, although a second injection may be required to achieve the desired success.